Somatic Cell Reprogramming via TGF-β Inhibition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for generating osteoblasts for regenerative medicine, such as direct reprogramming, face challenges including invasive cell collection, ethical concerns, and risks of tumorigenesis, as well as inefficiencies and costs associated with gene transfer techniques.

Innovation Solution

A method involving the use of TGF-β pathway inhibitors, specifically D4476, SB431542, LY2157299, or ALK5 inhibitor II, to convert differentiated somatic cells into other somatic cells, like osteoblasts or adipocytes, without gene transfer, by culturing them in a medium that suppresses the TGF-β/SMAD pathway.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If bone marrow cells are collected from cancellous bone for osteoblast generation, then autologous transplantation can be performed, but the collection process is highly invasive and insufficient cell numbers are obtained

Engineering Contradiction:

Improveautologous transplantation effectivenessVSAvoidcell collection invasiveness

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent uses TGF-β pathway inhibitors as an intermediary substance to mediate the conversion of easily obtainable somatic cells into osteoblasts, avoiding the need for invasive bone marrow collection while still achieving autologous transplantation goals

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If human embryonic stem cells are used for osteoblast generation, then sufficient cell numbers can be supplied without bone marrow collection, but ethical issues arise and tumorigenesis risk increases

Engineering Contradiction:

Improveosteoblast supply efficiencyVSAvoidtumorigenesis risk

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent employs readily available somatic cells as a temporary starting material that can be directly converted to osteoblasts without long-term culture, eliminating the need for expensive and risky pluripotent stem cells while maintaining high productivity

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent converts the previously harmful or limiting factor of cell differentiation state into a benefit by showing that differentiated somatic cells can be directly reprogrammed into osteoblasts, eliminating tumorigenesis risk while maintaining efficiency

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Productivity

If iPS cells are used for osteoblast generation, then sufficient cell numbers can be supplied without bone marrow collection, but tumorigenesis risk remains

Engineering Contradiction:

Improveosteoblast supply efficiencyVSAvoidtumorigenesis risk

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent uses easily obtainable somatic cells as a disposable starting material that undergoes direct conversion to osteoblasts, eliminating the need for iPS cell generation and associated tumorigenesis risks while maintaining high productivity

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

4Adaptability or versatility

If gene transfer techniques are used for direct reprogramming, then somatic cells can be converted to other cell types, but the process becomes complex and costly

Engineering Contradiction:

Improvecell type conversion capabilityVSAvoidgene transfer process complexity

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent replaces the complex mechanical/gene transfer system with a biochemical approach using TGF-β pathway inhibitors, simplifying the conversion process while maintaining versatility

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent achieves cell type conversion by changing the biochemical parameter of TGF-β pathway inhibition rather than introducing foreign genes, reducing process complexity while maintaining adaptability

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for the rapid generation of somatic cells, such as mesenchymal stem cells and osteoblasts, reducing immunological rejection and tumorigenesis risks, and enabling preclinical storage for allotransplantation or xenotransplantation, while avoiding the need for pluripotent stem cells.

Implementation Method 1

culturing them in a medium that suppresses the TGF-β/SMAD pathway

Methodology Applied

Scientific EffectTGF-β/SMAD pathway inhibition:

Data Source

PatentUS20240124842A1Cell preparation method

Publication Date: 2024.04.18 KYOTO PREFECTURAL PUBLIC UNIV CORP

AI summary

Provided is a method of preparing a somatic cell including converting a differentiated somatic cell of a mammal to other somatic cell by culturing the differentiated somatic cell in a medium for inducing differentiation of the somatic cell other than the differentiated somatic cell in the presence of a TGF-β pathway inhibitor.